CBD Gummies and Smoking Cessation: Marketing Claims Reviewed
Marketing claims CBD gummies make for smoking cessation often lack rigorous clinical evidence. Patients should be cautious and consult healthcare providers before use. This article reviews the evidence behind marketing claims CBD gummies present.
Insights on Cannabinoid Exposure in Substance Use Disorders
This 2026 review on cannabinoid exposure substance use disorders analyzes 97 studies with over 41,000 participants. It finds cannabinoids offer short-term symptom relief but lack durable efficacy for abstinence or relapse prevention. The evidence guides…
Lesser-known cannabis compounds show promise for treating alcohol addiction in rats
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
In the Mix: 3 More Articles — May 24, 2026
This article discusses cannabinoid pharmaceutical financial challenges impacting drug development in 2026. It highlights the economic struggles of companies developing cannabinoid therapies. Understanding these challenges is essential for clinicians…
In the Mix: 10 More Articles — May 20, 2026
This article reviews adolescent cannabis use disorder treatment delays and emerging clinical trends in 2026. It highlights the importance of monitoring cannabis mental health impacts in youth. Clinicians should consider regulatory developments affecting…
Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Beyond Dopamine: New Research Uncovers Multisystem Brain Networks in Addiction Mechanisms
Recent research highlights multisystem brain networks addiction as key in cannabis use disorder. This approach goes beyond dopamine to include endocannabinoid and stress pathways. Understanding these networks can improve clinical treatment outcomes.
In the Mix: 10 More Articles — May 19, 2026
This update features cannabis clinical updates May 2026 with 10 articles scored below the clinical relevance threshold. Topics include substance use patterns, regulatory developments, and emerging research. These cannabis clinical updates May 2026…
New study reveals distinct differences in how different drugs relate to criminal behavior
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Clearmind sets June 10 webinar on CMND-100 AUD trial – Stock Titan
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyMental HealthResearchAnxiety Why This Matters This webinar on CMND-100 addresses a potential pharmacological…